NCT03899259 · BASELINE

Baseline characteristics

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata · Source last updated 2026-04-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants

groups

description
* Week 0 to Week 52: Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind (Period 1). * Week 52 to Week 248: Participants continued to receive the same placebo or switched to either 2 mg or 4 mg Baricitinib dose administered orally QD (Period 2).
id
BG000
title
Placebo
description
* Week 0 to Week 52: Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind (Period 1). * Week 52 to Week 248: Participants continued to receive the same 2 mg dose or switched to an uptitrated 4 mg Baricitinib dose administered orally QD (Period 2).
id
BG001
title
2 mg Baricitinib
description
* Week 0 to Week 52: Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind (Period 1). * Week 52 to Week 248: Participants continued to receive the same 4 mg dose or switched to a downtitrated 2 mg Baricitinib dose, or receive placebo tablets matched to Baricitinib administered orally QD (Period 2).
id
BG002
title
4 mg Baricitinib
description
Total of all reporting groups
id
BG003
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
12.24
value
36.0
group Id
BG001
spread
12.96
value
38.2
group Id
BG002
spread
12.47
value
37.2
group Id
BG003
spread
12.55
value
37.2
denoms
counts
group Id
BG000
value
172
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
605
units
Participants
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
population Description
One participant was randomized inadvertently but not dosed and age was not obtained.
title
Age, Continuous
unit Of Measure
years
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
108
group Id
BG001
value
111
group Id
BG002
value
161
group Id
BG003
value
380
title
Female
measurements
group Id
BG000
value
65
group Id
BG001
value
63
group Id
BG002
value
98
group Id
BG003
value
226
title
Male
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
American Indian or Alaska Native
measurements
group Id
BG000
value
68
group Id
BG001
value
67
group Id
BG002
value
92
group Id
BG003
value
227
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
0
group Id
BG003
value
1
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
16
group Id
BG001
value
12
group Id
BG002
value
18
group Id
BG003
value
46
title
Black or African American
measurements
group Id
BG000
value
85
group Id
BG001
value
92
group Id
BG002
value
144
group Id
BG003
value
321
title
White
measurements
group Id
BG000
value
4
group Id
BG001
value
2
group Id
BG002
value
5
group Id
BG003
value
11
title
More than one race
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
Unknown or Not Reported
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
15
group Id
BG001
value
11
group Id
BG002
value
20
group Id
BG003
value
46
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Argentina
categories
measurements
group Id
BG000
value
17
group Id
BG001
value
17
group Id
BG002
value
20
group Id
BG003
value
54
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Australia
categories
measurements
group Id
BG000
value
14
group Id
BG001
value
13
group Id
BG002
value
24
group Id
BG003
value
51
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Brazil
categories
measurements
group Id
BG000
value
19
group Id
BG001
value
20
group Id
BG002
value
31
group Id
BG003
value
70
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
China
categories
measurements
group Id
BG000
value
14
group Id
BG001
value
19
group Id
BG002
value
25
group Id
BG003
value
58
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Israel
categories
measurements
group Id
BG000
value
10
group Id
BG001
value
11
group Id
BG002
value
20
group Id
BG003
value
41
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Japan
categories
measurements
group Id
BG000
value
23
group Id
BG001
value
17
group Id
BG002
value
26
group Id
BG003
value
66
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
South Korea
categories
measurements
group Id
BG000
value
7
group Id
BG001
value
12
group Id
BG002
value
11
group Id
BG003
value
30
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Taiwan
categories
measurements
group Id
BG000
value
54
group Id
BG001
value
54
group Id
BG002
value
82
group Id
BG003
value
190
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
United States
param Type
COUNT_OF_PARTICIPANTS
title
Region of Enrollment
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
17.75
value
84.6
group Id
BG001
spread
18.30
value
85.3
group Id
BG002
spread
18.03
value
84.9
group Id
BG003
spread
18.00
value
85.0
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
description
SALT uses a visual aid showing the division of the scalp hair into 4 areas - top of the head constituting 40% of total surface, the posterior/back of head 24%, right and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account for scoring. The score will range from 0% to 100%, with lower score indicating better health outcomes.
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Baseline Disease Severity of Alopecia Tool (SALT) Score
unit Of Measure
units on a scale

population Description

All randomized participants.

Complete source fields

denoms

counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants

groups

description
* Week 0 to Week 52: Participants received two placebo tablets matched to baricitinib, administered orally QD to maintain the blind (Period 1). * Week 52 to Week 248: Participants continued to receive the same placebo or switched to either 2 mg or 4 mg Baricitinib dose administered orally QD (Period 2).
id
BG000
title
Placebo
description
* Week 0 to Week 52: Participants received one 2 mg Baricitinib tablet administered orally QD and one placebo tablet administered orally QD to maintain the blind (Period 1). * Week 52 to Week 248: Participants continued to receive the same 2 mg dose or switched to an uptitrated 4 mg Baricitinib dose administered orally QD (Period 2).
id
BG001
title
2 mg Baricitinib
description
* Week 0 to Week 52: Participants received one 4 mg Baricitinib tablet and one placebo tablet administered orally QD to maintain the blind (Period 1). * Week 52 to Week 248: Participants continued to receive the same 4 mg dose or switched to a downtitrated 2 mg Baricitinib dose, or receive placebo tablets matched to Baricitinib administered orally QD (Period 2).
id
BG002
title
4 mg Baricitinib
description
Total of all reporting groups
id
BG003
title
Total

measures

classes
categories
measurements
group Id
BG000
spread
12.24
value
36.0
group Id
BG001
spread
12.96
value
38.2
group Id
BG002
spread
12.47
value
37.2
group Id
BG003
spread
12.55
value
37.2
denoms
counts
group Id
BG000
value
172
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
605
units
Participants
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
population Description
One participant was randomized inadvertently but not dosed and age was not obtained.
title
Age, Continuous
unit Of Measure
years
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
108
group Id
BG001
value
111
group Id
BG002
value
161
group Id
BG003
value
380
title
Female
measurements
group Id
BG000
value
65
group Id
BG001
value
63
group Id
BG002
value
98
group Id
BG003
value
226
title
Male
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Sex: Female, Male
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
American Indian or Alaska Native
measurements
group Id
BG000
value
68
group Id
BG001
value
67
group Id
BG002
value
92
group Id
BG003
value
227
title
Asian
measurements
group Id
BG000
value
0
group Id
BG001
value
1
group Id
BG002
value
0
group Id
BG003
value
1
title
Native Hawaiian or Other Pacific Islander
measurements
group Id
BG000
value
16
group Id
BG001
value
12
group Id
BG002
value
18
group Id
BG003
value
46
title
Black or African American
measurements
group Id
BG000
value
85
group Id
BG001
value
92
group Id
BG002
value
144
group Id
BG003
value
321
title
White
measurements
group Id
BG000
value
4
group Id
BG001
value
2
group Id
BG002
value
5
group Id
BG003
value
11
title
More than one race
measurements
group Id
BG000
value
0
group Id
BG001
value
0
group Id
BG002
value
0
group Id
BG003
value
0
title
Unknown or Not Reported
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
param Type
COUNT_OF_PARTICIPANTS
title
Race (NIH/OMB)
unit Of Measure
Participants
calculate Pct
false
classes
categories
measurements
group Id
BG000
value
15
group Id
BG001
value
11
group Id
BG002
value
20
group Id
BG003
value
46
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Argentina
categories
measurements
group Id
BG000
value
17
group Id
BG001
value
17
group Id
BG002
value
20
group Id
BG003
value
54
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Australia
categories
measurements
group Id
BG000
value
14
group Id
BG001
value
13
group Id
BG002
value
24
group Id
BG003
value
51
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Brazil
categories
measurements
group Id
BG000
value
19
group Id
BG001
value
20
group Id
BG002
value
31
group Id
BG003
value
70
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
China
categories
measurements
group Id
BG000
value
14
group Id
BG001
value
19
group Id
BG002
value
25
group Id
BG003
value
58
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Israel
categories
measurements
group Id
BG000
value
10
group Id
BG001
value
11
group Id
BG002
value
20
group Id
BG003
value
41
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Japan
categories
measurements
group Id
BG000
value
23
group Id
BG001
value
17
group Id
BG002
value
26
group Id
BG003
value
66
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
South Korea
categories
measurements
group Id
BG000
value
7
group Id
BG001
value
12
group Id
BG002
value
11
group Id
BG003
value
30
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
Taiwan
categories
measurements
group Id
BG000
value
54
group Id
BG001
value
54
group Id
BG002
value
82
group Id
BG003
value
190
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
title
United States
param Type
COUNT_OF_PARTICIPANTS
title
Region of Enrollment
unit Of Measure
Participants
classes
categories
measurements
group Id
BG000
spread
17.75
value
84.6
group Id
BG001
spread
18.30
value
85.3
group Id
BG002
spread
18.03
value
84.9
group Id
BG003
spread
18.00
value
85.0
denoms
counts
group Id
BG000
value
173
group Id
BG001
value
174
group Id
BG002
value
259
group Id
BG003
value
606
units
Participants
description
SALT uses a visual aid showing the division of the scalp hair into 4 areas - top of the head constituting 40% of total surface, the posterior/back of head 24%, right and left side of head 18% each. The percentage of hair loss in each area is determined and is multiplied by the percentage of scalp covered by that area. The total sum of the 4 products of each area will give the SALT score. Only terminal hair is included in the SALT; vellus hair or any fine downy hair is not taken into account for scoring. The score will range from 0% to 100%, with lower score indicating better health outcomes.
dispersion Type
STANDARD_DEVIATION
param Type
MEAN
title
Baseline Disease Severity of Alopecia Tool (SALT) Score
unit Of Measure
units on a scale

population Description

All randomized participants.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice